|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on January 2, 2003; DOI 10.1182/blood-2002-02-0570.
NEOPLASIA
From the Department of Pediatrics and Developmental
Biology, Postgraduate Medical School, Tokyo Medical and Dental
University, Tokyo, Japan; Radiobiology Division, National
Cancer Center Research Institute, Tokyo, Japan; Department
of Pediatrics, Hirosaki University School of Medicine, Aomori,
Japan; Department of Pediatrics, Showa University
Fujigaoka Hospital, Yokohama, Kanagawa, Japan; Department
of Pediatrics, Saga Medical School, Nabeshima, Saga,
Japan; and Department of Experimental Oncology, Istituto
Nazionale Tumori, Milano, Italy.
The possible involvement of germline mutation of the ataxia
telangiectasia mutated (ATM) gene in childhood
acute leukemia with mixed lineage leukemia (MLL) gene
rearrangement (MLL+) was investigated. Of the 7 patients studied, 1 showed a germline missense ATM mutation
(8921C>T; Pro2974Leu), located in the
phosphatidylinositol-3 (PI-3) kinase domain. In reconstitution assays,
the ATM mutant 8921T could only partially rescue the radiosensitive
phenotype of AT fibroblasts, and in an in vitro kinase assay, it showed a defective phosphorylation of p53-Ser15. Furthermore, the introduction of 8921T in U2OS cells, characterized by a normal ATM/p53 signal transduction, caused a significant reduction of in vivo p53-Ser15 phosphorylation, suggesting a dominant-negative effect of the mutant
ATM over the wild-type protein. Our finding in this patient suggests
that altered function of ATM plays some pathogenic roles in the
development of MLL+ leukemia.
(Blood. 2003;101:3622-3627) Ataxia telangiectasia (AT) is an autosomal
recessive disorder characterized by cerebellar ataxia, oculocutaneous
telangiectasia, and immunodeficiency. The responsible gene,
ATM (ataxia telangiectasia mutated), is located on
chromosome 11q22-23 and encodes a 350-kDa nuclear protein with a
carboxy-terminal domain similar to the catalytic subunit of the
phosphatidylinositol-3 kinases (PI-3 kinases).1-3 PI-3
kinase-related proteins are known to function in the maintenance of
genomic stability, cell cycle control, and cellular responses to DNA
damage.4,5 AT cells exhibit hypersensitivity to ionizing
radiation and are defective at multiple cell cycle checkpoints.4-7
It is well established that patients with AT are at increased risk of
cancer,8 in particular, neoplasms of lymphoid
origin.9,10 Somatic mutations in the ATM gene
have been identified in patients with T-cell prolymphocytic leukemia
(T-PLL)11 and B-cell chronic lymphocytic leukemia (B-CLL)
with no family history of AT.12-14 Mutations observed in
these reports are missense mutations and most occur in the PI-3 kinase
domain. Heterozygous germline missense mutations were also found among
B-CLL patients, indicating that such genetic alterations might act as
predisposing factors for the development of lymphoid
tumors.12,13 The germline missense ATM
mutations have been reported in patients with breast carcinoma with
early onset disease and positive family history.15
The chromosomal translocation of the mixed lineage leukemia
(MLL) gene at 11q23 is involved in a subset of childhood
leukemia, most frequently in infantile leukemia.16-18 The
MLL gene rearrangement is also involved in treatment-related
leukemias secondary to chemotherapy using topoisomerase II (topo II)
inhibitors. This has led to the hypothesis that in utero exposure to
chemicals, such as certain antibiotics, laxatives, podophyllin resins,
flavonoids, herbal medicines, and benzene metabolites may cause
infantile leukemia via an effect on topo II.19,20 Recent
epidemiologic data indicate that maternal alcohol exposure and exposure
to recreational drugs, pesticides, and anti-inflammatory drugs increase
the risk of infantile leukemia.21-23 Thus, environmental
factors appear to play an important role in the development of
this disease.
Previous studies have shown that AT cells are hypersensitive to topo II
inhibitors.24-28 It is plausible that mixed lineage leukemia (MLL) gene rearrangement (MLL+)
leukemias such as infantile leukemia could arise in individuals with hypersensitivity to topo II inhibitors, and this hypothesis led us
to investigate ATM gene mutation in patients who had
developed MLL+ leukemia. In this study, we attempted to
determine whether the germline ATM gene mutation could
represent one genetic factor for predisposition to MLL+
leukemia in children and whether it could play a role in the pathogenesis of this condition.
Patients
MLL gene rearrangement was determined by the method
described previously.29
Epstein-Barr virus (EBV)-immortalized lymphoblastoid cell lines
(L-1-L-7, LCL-wt1, LCL-wt2) were established by infecting normal
lymphocytes obtained from the patients and 2 healthy volunteers with
EBV strain B95-8 as previously described.30 Immortalized lymphoblastoid cell lines (LCLs) were maintained in RPMI 1640 (Gibco
BRL Life Technologies, Gaithersburg, MD) with 15% fetal calf serum
(FCS; Gibco BRL) at approximately 5 × 105 cells/mL at
37°C in 5% CO2. The SV40-transformed AT cell line GM05849C (7009delTG) was obtained from Coriell Cell Repositories (Camden, NJ). The osteosarcoma cell line U2OS and human embryonic kidney cell line 293 were obtained from Health Science Research Resources Bank (Osaka, Japan).
PCR/DNA sequencing
Microsatellite analysis Microsatellite analysis at chromosome 11q neighboring or intragenic to ATM was performed as described.31 Briefly, the microsatellite markers D11S2178, D11S1294, D11S1778, D11S2179, D11S2366, and D11S1787 were selected. The forward primer of each pair was 5'-labeled with HEX or 6-FAM dye. Template DNA was amplified by touchdown PCR using AmpliTaq Gold (Applied Biosystems).PCR/RFLP analysis Allele frequency of the mutation was analyzed using the PCR/restriction fragment length polymorphism (RFLP) method. For the 8921C>T nucleotide change, digestion with AlwNI (New England Biolabs, Beverly, MA) yielded 2 bands for exon 64 of mutant ATM. For the 787A>G nucleotide change, digestion
with SacII (Takara) yielded 2 bands and 3 bands for exon 2 of wild-type ATM and mutant ATM, respectively.
This analysis was also used to detect the expression level of 8921T
ATM mRNA in transfectants and L-4 LCL.
Subcloning of the ATM allele RNA was obtained from 1 × 106 EB-transformed cells using the Dynabeads RNA extraction kit (Dynabeads, Oslo, Norway). ATM partial sequence (7012-9402) was amplified using LA Taq (Takara) followed by cDNA synthesis using reverse transcriptase XL (Takara). Amplified cDNA was subcloned into the pGEM-T Easy TA cloning system (Promega, Madison, WI). The plasmid, which contained the corresponding nucleotide change of the ATM gene, was digested with PflMI (New England Biolabs) and SalI (Takara), and the insert was subcloned into PflMI and XhoI (Takara) sites of pcDNA3-YZ5 using Ligation Kit Ver II (Takara). The expression vector thus constructed (pcDNA3/8921T) was subjected to DNA sequencing analysis and was found to have wild-type sequence except for the 8921T change.Western blot analysis Cells (1 × 106) were washed with phosphate-buffered saline (PBS) and lysed in 150 mM NaCl, 1.0% NP-40, 0.1% sodium dodecyl sulfate (SDS), 0.1% sodium deoxycholate, 5 mM EDTA (ethylenediaminetetraacetic acid), and 10 mM Tris (tris(hydroxymethyl)aminomethane)-HCl (pH 7.4) containing protease inhibitors. Protein concentrations were measured using the DC protein assay (Bio-Rad, Hercules, CA). After boiling with sample buffer, 30 µg protein was subjected to SDS-polyacrylamide gel electrophoresis (PAGE). After transfer to polyvinylidine difluoride (PVDF) membrane (Millipore, Bedford, MA), the blots were probed with an anti-p53-Ser15 phosphospecific antibody (New England Biolabs), anti-ATM antibody,32 or anti- -tubulin (Oncogene
Science, Cambridge, MA) antibody. Horseradish peroxidase
(HRP)-conjugated antirabbit or antimouse antibody (Amersham,
Buckinghamshire, England) was used as the secondary antibody.
Clonogenic assay Plasmid pcDNA3, pcDNA3-YZ5, or pcDNA3-YZ5/8921T was transfected into GM05849C (Effecten; Qiagen, Hilden, Germany) and stable clones were selected with 500 µg/mL neomycin (Sigma, St Louis, MO). Cells were trypsinized, plated onto 60-mm dishes at a density of 7 to 10 × 103 cells/dish, and incubated for 17 hours. Then cells were exposed to a range of doses of x-irradiation (X-IR) at 0 to 5 Gy followed by incubation for 10 days at 37°C in 5% CO2. Prior to counting colonies, the culture medium was decanted and the cells were fixed in 95% methanol and stained with 0.5% crystal violet, and the numbers of colonies (> 50 cells) from triplicate dishes were counted. Mean colony numbers relative to unirradiated colony numbers were plotted.Kinase assay The 293 cells were transiently transfected by FLAG-tagged pcDNA3-YZ5 or pcDNA3-YZ5/8921T. Cells (2 × 107) were washed with PBS and lysed in TGN buffer (150 mM NaCl, 0.3% NP-40, 1% Tween, and 50 mM Tris-HCl [pH 7.5] containing protease inhibitors). Cell lysate (500 µg) was precleared by constant mixing for 1 hour with protein A-Sepharose beads (Pharmacia Biotech, Uppsala, Sweden). The beads were removed by centrifugation, and the supernatant was mixed for 1 hour with anti-FLAG M2 monoclonal antibody (Sigma). Immune complexes were adsorbed onto protein A-Sepharose and then washed twice with TGN buffer, twice with TGN buffer plus 0.5 M LiCl, and twice with kinase buffer (20 mM HEPES [N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid], pH 7.5, 50 mM NaCl, 10 mM MgCl2, 1 mM dithiothreitol, and 10 mM MnCl2) and incubated with GST-p53 (amino acids 1-100) in 20 mM Tris HCl buffer (pH 7.6; 10 mM MgCl2, 10 mM MnCl2, 50 mM adenosine triphosphate [ATP]), containing 100 µM ATP for 30 minutes at 30°C. Anti-p53 phosphoserine 15 antibody was used to detect phosphorylation of Ser15 of GST-p53 (amino acids 1-100).
Nucleotide change of the ATM gene To search for ATM mutations, we sequenced the open reading frame (ORF) of ATM cDNA using RT-PCR-based direct sequencing. L-4 was identified to have a nucleotide change of 8921C>T on one allele (Figure 1). The 8921C>T transversion results in a Pro Leu amino acid change at codon 2974 within the PI-3 kinase domain. Thus, L-4 was determined to be
heterozygous (wt/8921T) at the ATM gene.
The same nucleotide change was confirmed in fresh peripheral lymphocyte genomic DNA from patient L-4 (data not shown). Furthermore, the father of patient L-4 was demonstrated to have the same nucleotide change on one of the alleles (data not shown), indicating paternal inheritance of this nucleotide change. We also analyzed for the presence or absence of wild-type allele in leukemic cells of patient L-4 by microsatellite analysis, and no loss of heterozygosity (LOH) was identified (supplemental data on the Blood website; see the Supplemental Figure link at the top of the online article). We screened 166 samples from an archive of DNA stock of unselected neonatal cord blood for detection of this nucleotide change using RT-PCR/RFLP analysis and direct sequencing. One sample was heterozygous for 8921C>T, resulting in an allele frequency of 0.3%. Biologic activity of 8921T ATM It is well established that AT cells are hypersensitive to ionizing radiation.6,7,33 To determine whether the 8921T nucleotide change, which is located within the PI-3 kinase domain, can rescue the radiosensitive phenotype of an AT cell line (ATM /), we transfected pcDNA3 (vector alone),
pcDNA3-YZ5 (wild-type ATM), or pcDNA3-YZ5/8921T (mutant ATM) into the
AT fibroblast cell line GM05849C. Stable clones expressing comparable
amounts of wild-type or 8921T ATM protein were isolated (Figure
2B) and analyzed for clonogenic cell
survival after exposure to variable doses of irradiation.
pcDNA3-YZ5/8921T showed only partial rescue of the radiosensitive
phenotype of GM05849C, when compared with pcDNA3-YZ5 (Figure
2A).
ATM directly phosphorylates p53 at Ser15 in response to X-IR-induced
DNA damage.34,35 Phosphorylation of Ser15 is a necessary step for p53 accumulation and p53-dependent
transactivation.36,37 Rapid phosphorylation of p53 at
Ser15 in response to X-IR is reduced in AT cells and cells from some
obligate AT heterozygous carriers.32 To examine the
ability of the 8921T ATM to phosphorylate p53-Ser15, we transiently
transfected 293 cells with pcDNA3-YZ5 or pcDNA3-YZ5/8921T and in vitro
kinase activity was assessed using anti-FLAG-tagged immunoprecipitates. The 8921T exhibited about 60% less p53-Ser15 phosphorylation activity (Figure 3),
suggesting that this is a genuine mutation rather than a
polymorphic variant.
Dominant-negative effect of the 8921T mutation An issue of great interest was to determine whether the 8921T mutant protein interferes with the normal ATM function. We transfected U2OS cells, which exhibit normal ATM-dependent p53-Ser15 phosphorylation activity, with a mock or pcDNA3-YZ5/8921T mutant ATM expression vector, and in vivo p53-Ser15 phosphorylation was examined by Western blotting. We isolated 2 independent U2OS clones expressing wild-type and 8921T ATM at a ratio of 1:0.1 (clone 1) and 1:0.8 (clone 2), and assayed for p53-Ser15 phosphorylation 30 minutes after X-IR. The phosphorylation level was reduced by approximately 30% and 50% in clone 1 and clone 2, respectively, when compared with mock transfectant (Figure 4).
In vivo phosphorylation of p53 at Ser15 in L-4 The finding that 8921T has a dominant-negative activity in transfection assay lead us to study in vivo p53-Ser15 phosphorylation in L-4 immediately after X-IR. RT-PCR/RFLP analysis allowed us to determine that the expression level of 8921T allele was comparable to that of wild-type allele in L-4 (Figure 5A). At 15 and 30 minutes after 5-Gy X-IR, L-4 exhibited a 40% to 80% reduction in phosphorylation compared with 2 normal control LCLs (LCL-wt1, LCL-wt2) and L-6 with no ATM mutation (Figure 5B-C). We noted an unexpected finding that L-2, with no detectable mutation within the ORF of ATM (data not shown), also demonstrated a significant decrease in p53-Ser15 phosphorylation (Figure 5C). ATM and Rad-3-related (ATR) kinase also phosphorylates p53-Ser15 1 hour after X-IR, whereas ATM acts immediately.38 Therefore, the level of p53-Ser15 phosphorylation at 60 minutes in this assay was less informative with regard to ATM activity.
Normal expression of ATM protein in L-4 In most heterozygous AT carriers, the ATM protein level is reduced due to truncation mutations.32 However, in the case of missense mutation (7271T>G), the ATM protein is expressed at normal level.39 Thus, ATM protein expression was studied by Western blotting in L-4 and L-2, the latter showing no mutation of ATM gene but poor p53 phosphorylation activity. The level of ATM protein expression in L-4 was comparable with those seen both in normal LCL-wt1 and in the remaining LCLs, except for L-2 (data not shown for L-5, L-6, and L-7). In L-2, the ATM protein was approximately 37% of normal LCL-wt1 (Figure 6A-B). ATM mRNA expression in L-2 was reduced by 30% as analyzed by semiquantitative RT-PCR assay (data not shown). L-2, however, showed no mutation in ORF of ATM gene. Thus, we sequenced the 5' and partial 3' untranslated region (UTR) of the ATM gene and identified the787A>G nucleotide change (data not shown). Subsequent
analysis in 100 Japanese cord blood samples revealed a 61% allele
frequency of 787A>G and this was considered as a normal polymorphism
(data not shown). Thus, the reason for the decreased ATM expression in
L-2 requires further investigation.
AT homozygotes and heterozygotes are reportedly hypersensitive to topo II inhibitors, such as etoposide (VP16).40 The finding that the plant isoflavenoid genistein (that has topo II inhibitor activity), activates p53 and Chk2 in an ATM-dependent manner41 further suggests an important link between topo II inhibitors and ATM. Epidemiologic data indicate a significant association between infantile leukemia and maternal exposures to topo II inhibitors or topo II inhibitor-like chemicals,42 which are known to cause intracellular rearrangement of the MLL gene.19,20 These findings led us to hypothesize that at least some leukemias with MLL gene rearrangement may develop in individuals with a combination of hypersensitivity to topo II inhibitors as characterized by genetic ATM dysfunction and environmental effects, such as exposure to topo II inhibitors. In the present study, a heterozygous germline mutation (8921C>T) in
the PI-3 kinase domain of the ATM gene was identified in a
case (L-4) of MLL+ leukemia. L-4 expressed an apparently
normal level of ATM protein. 8921T is associated with amino acid
substitution of Pro2974Leu, which leads to a change in the secondary
structure of the ATM protein, namely, loss of random coil between
The ATM protein is known to multimerize and to associate with other proteins, forming a functional complex.45 Gatti et al have hypothesized that there are 2 types of ATM heterozygotes, those with truncating mutations making no protein, and those with missense mutations making the mutant protein.46 Presence of the mutant protein in such a complex may disrupt its function, leading to a dominant-negative effect against wild-type ATM protein.46,47 In addition, it has been reported that overexpression of a kinase dead ATM cDNA has a dominant interfering effect on ATM kinase activity.48 During the preparation of this manuscript, Scott et al have shown that a missense mutation (7775C>G) of ATM gene identified in a breast cancer patient has a dominant-negative effect against wild-type ATM.45 Furthermore, Spring et al reported that mice heterozygous for Atm mutation (7636del9) but not for truncation mutation, showed an increased susceptibility to developing tumors.49 In a segregation analysis, the father of patient L-4 was heterozygous for the 8921T mutation, excluding the possibility that the alteration arose de novo in the patient. The father, however, remains free from malignant disease to date. These results suggest that the 8921T mutation has a relatively low penetrance, and the environmental stresses, such as exposure to topo II inhibitors at certain developmental stages, played a critical role in the development of MLL+ leukemia in this case. This is important in light of the finding that allele frequency of 8921T was 0.3% in normal cord blood samples. Thus, although further extensive studies are required to justify our hypothesis, our findings suggest that dysregulation of ATM/p53 signal transduction cascade in response to environmental stresses may be one of the possible genetic factors underlying the pathogenesis of MLL+ leukemia. Further study is required to better understand the role of ATM dysfunction with regard to the disease susceptibility and exposures to DNA-damaging agents.
We are grateful to Dr M. Kastan for the kind gift of pcDNA3-YZ5.
Submitted February 21, 2002; accepted December 10, 2002.
Prepublished online as Blood First Edition Paper, January 2, 2003; DOI 10.1182/blood-2002-02-0570.
Supported by a Grant-in-Aid for Pediatric Research from the Ministry of Health and Welfare, Japan, by a Grant-in-Aid for Cancer Research from the Ministry of Health and Welfare, Japan, and by a Grant-in-Aid from the Ministry of Health and Welfare, Japan, as part of a comprehensive 10-year strategy for Cancer Control; by a Grant-in-Aid from the Ministry of Education, Science and Culture, Japan; by a Grant from the Human Science Foundation, Japan; by a Grant from the Japan Leukemia Research Fund; and by the Italian Association for Cancer Research (AIRC) and Telethon grants E764 and GPO205/01. L.Z. is supported by a fellowship from the Italian Foundation for Cancer Research (FIRC).
K.O. and M.T. contributed equally to this work.
The online version of the article contains a data supplement.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Shuki Mizutani, Department of Pediatrics and Developmental Biology, Postgraduate Medical School, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo 113-8519, Japan; e-mail: smizutani.ped{at}tmd.ac.jp.
1. Savitsky K, Bar SA, Gilad S, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science. 1995;268:1749-1753. 2. Savitsky K, Sfez S, Tagle DA, et al. The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Hum Mol Genet. 1995;4:2025-2032. 3. Brown KD, Ziv Y, Sadanandan SN, et al. The ataxia-telangiectasia gene product, a constitutively expressed nuclear protein that is not up-regulated following genome damage. Proc Natl Acad Sci U S A. 1997;94:1840-1845. 4. Zakian VA. ATM-related genes: what do they tell us about functions of the human gene? Cell. 1995;82:685-687. 5. Hoekstra MF. Responses to DNA damage and regulation of cell cycle checkpoints by the ATM protein kinase family. Curr Opin Genet Dev. 1997;7:170-175. 6. Canman CE, Wolff AC, Chen CY, Fornace AJ, Kastan MB. The p53-dependent G1 cell cycle checkpoint pathway and ataxia-telangiectasia. Cancer Res. 1994;54:5054-5058. 7. Takagi M, Delia D, Chessa L, et al. Defective control of apoptosis, radiosensitivity, and spindle checkpoint in ataxia telangiectasia. Cancer Res. 1998;58:4923-4929. 8. Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med. 1991;325:1831-1836. 9. Murphy RC, Berdon WE, Ruzal-Shapiro C, et al. Malignancies in pediatric patients with ataxia telangiectasia. Pediatr Radiol. 1999;29:225-230. 10. Taylor AM, Metcalfe JA, Thick J, Mak YF. Leukemia and lymphoma in ataxia telangiectasia. Blood. 1996;87:423-438. 11. Vorechovsky I, Luo L, Dyer MJ, et al. Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia. Nat Genet. 1997;17:96-99. 12. Bullrich F, Rasio D, Kitada S, et al. ATM mutations in B-cell chronic lymphocytic leukemia. Cancer Res. 1999;59:24-27. 13. Stankovic T, Weber P, Stewart G, et al. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet. 1999;353:26-29. 14. Schaffner C, Stilgenbauer S, Rappold GA, Dohner H, Lichter P. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood. 1999;94:748-753. 15. Teraoka SN, Malone KE, Doody DR, et al. Increased frequency of ATM mutations in breast carcinoma patients with early onset disease and positive family history. Cancer. 2001;92:479-487. 16. Greaves MF. Infant leukaemia biology, aetiology and treatment. Leukemia. 1996;10:372-377. 17. Poirel H, Rack K, Delabesse E, et al. Incidence and characterization of MLL gene (11q23) rearrangements in acute myeloid leukemia M1 and M5. Blood. 1996;87:2496-2505. 18. Thirman MJ, Gill HJ, Burnett RC, et al. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N Engl J Med. 1993;329:909-914. 19. Ross JA, Potter JD, Robison LL. Infant leukemia, topoisomerase II inhibitors, and the MLL gene. J Natl Cancer Inst. 1994;86:1678-1680. 20. Strick R, Strissel PL, Borgers S, Smith SL, Rowley JD. Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia. Proc Natl Acad Sci U S A. 2000;97:4790-4795. 21. Ross JA, Davies SM, Potter JD, Robison LL. Epidemiology of childhood leukemia, with a focus on infants. Epidemiol Rev. 1994;16:243-272. 22. Shu XO, Ross JA, Pendergrass TW, Reaman GH, Lampkin B, Robison LL. Parental alcohol consumption, cigarette smoking, and risk of infant leukemia: a Childrens Cancer Group study. J Natl Cancer Inst. 1996;88:24-31. 23. Alexander FE, Patheal SL, Biondi A, et al. Transplacental chemical exposure and risk of infant leukemia with MLL gene fusion. Cancer Res. 2001;61:2542-2546. 24. Caporossi D, Porfirio B, Nicoletti B, et al. Hypersensitivity of lymphoblastoid lines derived from ataxia telangiectasia patients to the induction of chromosomal aberrations by etoposide (VP-16). Mutat Res. 1993;290:265-272. 25. Davies SM, Harris AL, Hickson ID. Overproduction of topoisomerase II in an ataxia telangiectasia fibroblast cell line: comparison with a topoisomerase II-overproducing hamster cell mutant. Nucleic Acids Res. 1989;17:1337-1351. 26. Smith P, Makinson T. Cellular consequences of overproduction of DNA topoisomerase II in an ataxia-telangiectasia cell line. Cancer Res. 1989;49:1118-1124. 27. Henner WD, Blazka ME. Hypersensitivity of cultured ataxia-telangiectasia cells to etoposide. J Natl Cancer Inst. 1986;76:1007-1011. 28. Petrinelli P, Elli R, Marcucci L, Barbieri C, Ambra R, Antonelli A. VP16 hypersensitivity and increased faulty recombination in ataxia telangiectasia lymphocytes characterized by the tandem translocation t(14;14)(q11;q32). Carcinogenesis. 1996;17:203-207. 29. Kawasaki H, Isoyama K, Eguchi M, et al. Superior outcome of infant acute myeloid leukemia with intensive chemotherapy: results of the Japan Infant Leukemia Study Group. Blood. 2001;98:3589-3594. 30. Pelloquin F, Lamelin JP, Lenoir GM. Human B lymphocytes immortalization by Epstein-Barr virus in the presence of cyclosporin A. In Vitro Cell Dev Biol. 1986;22:689-694. 31. Izatt L, Greenman J, Hodgson S, et al. Identification of germline missense mutations and rare allelic variants in the ATM gene in early-onset breast cancer. Genes Chromosomes Cancer. 1999;26:286-294. 32. Delia D, Mizutani S, Panigone S, et al. ATM protein and p53-serine 15 phosphorylation in ataxia-telangiectasia (AT) patients and at heterozygotes. Br J Cancer. 2000;82:1938-1945. 33. Thacker J. Cellular radiosensitivity in ataxia-telangiectasia. Int J Radiat Biol. 1994;66:S87-S96. 34. Banin S, Moyal L, Shieh S, et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science. 1998;281:1674-1677. 35. Canman CE, Lim DS, Cimprich KA, et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science. 1998;281:1677-1679. 36. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387:296-299. 37. Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell. 1997;91:325-334. 38. Tibbetts RS, Brumbaugh KM, Williams JM, et al. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev. 1999;13:152-157.
39.
Stewart GS, Last JI, Stankovic T, et al.
Residual ataxia telangiectasia mutated protein function in cells from ataxia telangiectasia patients, with 5762ins137 and 7271T 40. Pernin D, Bay JO, Uhrhammer N, Bignon YJ. ATM heterozygote cells exhibit intermediate levels of apoptosis in response to streptonigrin and etoposide. Eur J Cancer. 1999;35:1130-1135. 41. Ye R, Bodero A, Zhou BB, Khanna KK, Lavin MF, Lees-Miller SP. The plant isoflavenoid genistein activates p53 and Chk2 in an ATM-dependent manner. J Biol Chem. 2001;276:4828-4833. 42. Greaves MF. Aetiology of acute leukaemia. Lancet. 1997;349:344-349. 43. Garnier J, Gibrat JF, Robson B. GOR method for predicting protein secondary structure from amino acid sequence. Methods Enzymol. 1996;266:540-553. 44. Pettitt AR, Sherrington PD, Stewart G, Cawley JC, Taylor AM, Stankovic T. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood. 2001;98:814-822. 45. Scott SP, Bendix R, Chen P, Clark R, Dork T, Lavin MF. Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer. Proc Natl Acad Sci U S A. 2002;99:925-930. 46. Gatti RA, Tward A, Concannon P. Cancer risk in ATM heterozygotes: a model of phenotypic and mechanistic differences between missense and truncating mutations. Mol Genet Metab. 1999;68:419-423. 47. Khanna KK. Cancer risk and the ATM gene: a continuing debate. J Natl Cancer Inst. 2000;92:795-802. 48. Lim DS, Kim ST, Xu B, et al. ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway. Nature. 2000;404:613-617. 49. Spring K, Ahangari F, Scott SP, et al. Mice heterozygous for mutation in Atm, the gene involved in ataxia-telangiectasia, have heightened susceptibility to cancer. Nat Genet. 2002;32:185-190.
© 2003 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  V. Stagni, M. G. di Bari, S. Cursi, I. Condo, M. T. Cencioni, R. Testi, Y. Lerenthal, E. Cundari, and D. Barila ATM kinase activity modulates Fas sensitivity through the regulation of FLIP in lymphoid cells Blood, January 15, 2008; 111(2): 829 - 837. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Liu, E. H.-Y. Cheng, and J. J.-D. Hsieh Bimodal degradation of MLL by SCFSkp2 and APCCdc20 assures cell cycle execution: a critical regulatory circuit lost in leukemogenic MLL fusions Genes & Dev., October 1, 2007; 21(19): 2385 - 2398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Sakasai, K. Shinohe, Y. Ichijima, N. Okita, A. Shibata, K. Asahina, and H. Teraoka Differential involvement of phosphatidylinositol 3-kinase-related protein kinases in hyperphosphorylation of replication protein A2 in response to replication-mediated DNA double-strand breaks Genes Cells, March 1, 2006; 11(3): 237 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. J. Weston, B. Austen, W. Wei, E. Marston, A. Alvi, S. Lawson, P. J. Darbyshire, M. Griffiths, F. Hill, J. R. Mann, et al. Apoptotic resistance to ionizing radiation in pediatric B-precursor acute lymphoblastic leukemia frequently involves increased NF-{kappa}B survival pathway signaling Blood, September 1, 2004; 104(5): 1465 - 1473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Takagi, R. Tsuchida, K. Oguchi, T. Shigeta, S. Nakada, K. Shimizu, M. Ohki, D. Delia, L. Chessa, Y. Taya, et al. Identification and characterization of polymorphic variations of the ataxia telangiectasia mutated (ATM) gene in childhood Hodgkin disease Blood, January 1, 2004; 103(1): 283 - 290. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
